Frazier Financial Advisors, LLC Mersana Therapeutics, Inc. Transaction History
Frazier Financial Advisors, LLC
- $129 Billion
- Q3 2024
A detailed history of Frazier Financial Advisors, LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Frazier Financial Advisors, LLC holds 5 shares of MRSN stock, worth $12. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5
Previous 5
-0.0%
Holding current value
$12
Previous $11,000
9.09%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding MRSN
# of Institutions
123Shares Held
115MCall Options Held
73.5KPut Options Held
46.4K-
Eco R1 Capital, LLC San Francisco, CA19.4MShares$49 Million1.38% of portfolio
-
Vr Adviser, LLC New York, NY11.3MShares$28.7 Million2.5% of portfolio
-
Nextech Invest Ag9.53MShares$24.1 Million3.61% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$21.9 Million3.56% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$21.2 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $246M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...